Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for hard-to-treat t-cell lymphoma: drug combo plus radiation before transplant

NCT ID NCT07225985

Recruiting now Disease control Sponsor: Fred Hutchinson Cancer Center Source: ClinicalTrials.gov ↗

First seen Nov 11, 2025 · Last updated Apr 28, 2026 · Updated 21 times

Summary

This study tests a new mix of two drugs (pralatrexate and bendamustine) plus low-dose total-body radiation before a donor stem cell transplant for people with T-cell lymphoma that has returned or not responded to treatment. The goal is to safely prepare the body for the transplant and kill remaining cancer cells. About 50 adults will take part to find the best dose and see if this approach helps more patients get to transplant.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT T-CELL NON-HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fred Hutch/University of Washington Cancer Consortium

    RECRUITING

    Seattle, Washington, 98109, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.

RECURRENT T-CELL NON-HODGKIN LYMPHOMA REFRACTORY T-CELL NON-HODGKIN LYMPHOMA